Stockscreener 앱 받기
7.26
4.72%
-0.36
시간 외 거래:
7.26
Precision Biosciences Inc 주식(DTIL)의 최신 뉴스
Trading (DTIL) With Integrated Risk Controls - Stock Traders Daily
Gene Editing Tools Market Size, Growth Opportunities, - openPR
Precision BioSciences Reports 99% HBV Gene Editing Success, Unveils Phase 1 Trial Design | DTIL Stock News - StockTitan
JANUS HENDERSON GROUP PLC's Strategic Acquisition in Precision B - GuruFocus.com
Precision BioSciences stock hits 52-week low at $7.94 By Investing.com - Investing.com Canada
Precision BioSciences stock hits 52-week low at $7.94 - Investing.com
Highbridge Capital Management's Strategic Acquisition of Precisi - GuruFocus.com
What is HC Wainwright's Forecast for DTIL FY2024 Earnings? - MarketBeat
Research Analysts Offer Predictions for DTIL FY2027 Earnings - MarketBeat
(DTIL) Technical Data - Stock Traders Daily
Precision Biosciences CEO Michael Amoroso sells shares worth $24,668 - Investing.com India
Precision Biosciences' general counsel sells $4,815 in stock - Investing.com
Precision Biosciences CEO Michael Amoroso sells shares worth $24,668 By Investing.com - Investing.com UK
Precision BioSciences keeps $34 target, Market Perform rating By Investing.com - Investing.com Australia
Precision BioSciences: Q3 Earnings Snapshot - Darien Times
Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace
Precision BioSciences keeps $34 target, Market Perform rating - Investing.com
Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains? - MSN
Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma - Marketscreener.com
Precision BioSciences (DTIL) Set to Announce Earnings on Monday - MarketBeat
Precision BioSciences to Report Third Quarter Results on November 4, 2024 - BioSpace
Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024 - Business Wire
(DTIL) Trading Report - Stock Traders Daily
Precision BioSciences stock hits 52-week low at $8.22 By Investing.com - Investing.com Canada
500: Something went wrong - Investing.com
Precision BioSciences stock hits 52-week low at $8.22 - Investing.com India
Precision BioSciences begins clinical trial for hepatitis B cure By Investing.com - Investing.com Australia
Precision BioSciences touts gene editing efficiency with ARCUS - Investing.com India
Precision BioSciences touts gene editing efficiency with ARCUS By Investing.com - Investing.com Canada
Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress - Business Wire
Precision BioSciences to Report Q3 Earnings: What's in the Cards? - Yahoo Finance
Precision BioSciences, Inc. announced that it has received $25.65 million in funding from a group of investors. - Marketscreener.com
Precision BioSciences begins clinical trial for hepatitis B cure - Investing.com
Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B - Business Wire
Precision BioSciences Advances Gene Editing Trials Globally - TipRanks
Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences - BioSpace
Short Interest in Precision BioSciences, Inc. (NASDAQ:DTIL) Drops By 7.1% - MarketBeat
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress - BioSpace
How the (DTIL) price action is used to our Advantage - Stock Traders Daily
Gene Editing Tools Market Poised for Massive Growth (2024-2031) - openPR
(DTIL) Investment Report - Stock Traders Daily
3.66%
1.11%
자본화:
|
볼륨(24시간):